Compounded medications have become routine across a wide range of practices, from hormone therapy and dermatology to aesthetics, fertility, ophthalmology, and weight management. Providers prescribe them because a commercially available product does not fit the patient, because of a shortage, or because a compounded formulation is simply the practical option.
What many providers do not realize is that the decision to prescribe or administer a compounded drug can interact with an exclusion buried in their medical professional liability policy. The logic runs through a single fact that surprises a lot of clinicians: compounded medications are not FDA approved, and using a registered 503B outsourcing facility does not change that.
Here is how the regulatory picture actually works, and why it matters to your coverage.
Compounded Drugs Are Not FDA Approved
This is the foundation of the issue, and it comes straight from the FDA. Compounded drugs do not go through the agency’s premarket approval process. As the FDA states in its guidance on compounded drug products, drugs compounded by outsourcing facilities have not undergone FDA premarket review for safety, effectiveness, and quality, and they lack the premarket inspection and finding of manufacturing quality that is part of the drug approval process.
That is not a criticism of compounding, which serves a genuine clinical need. It is a statement about regulatory status. An FDA-approved drug has been evaluated by the agency for safety and efficacy for a specific indication. A compounded drug has not, regardless of how carefully it was prepared.
The FDA’s position on clinical use follows this. The agency advises that patients should use an FDA-approved product when one is available that meets their needs, and reserves compounded medications for situations where an approved product does not fit the patient.
503A and 503B: What the Distinction Actually Means
The Drug Quality and Security Act created two categories of compounding, and the difference between them is widely misunderstood.
Section 503A covers compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician, that is not registered as an outsourcing facility. These are traditional patient-specific prescriptions, overseen primarily at the state level. Per the FDA’s comparison of the two sections, drugs compounded under 503A are not subject to current good manufacturing practice requirements.
Section 503B covers compounding within a registered outsourcing facility. These facilities can compound in larger batches, including without patient-specific prescriptions, and they operate under meaningfully greater federal oversight. The FDA confirms in its compounding questions and answers that outsourcing facilities registered under 503B are primarily overseen by FDA and inspected according to a risk-based schedule, and that drugs compounded in outsourcing facilities are subject to CGMP requirements, unlike those compounded under 503A.
The Critical Point: 503B Registration Is Not FDA Approval
This is where clinical practices can get into trouble. A facility appearing on the FDA’s 503B outsourcing facility list has registered with the agency, is subject to CGMP requirements, and is subject to FDA inspection. Those are real, substantive quality assurances, and sourcing from a 503B facility is generally the more conservative choice.
None of it makes the compounded drug itself FDA approved. The FDA is explicit that drug products compounded by outsourcing facilities in accordance with section 503B are exempt from FDA drug approval requirements. Registration describes the facility. Approval describes the product. They are not the same thing, and the 503B list is not a list of approved medications.
There are additional constraints worth knowing. Outsourcing facilities may not compound a drug using a bulk drug substance unless that substance appears on the FDA’s 503B bulks list or the compounded product appears on the FDA’s drug shortage list at the time of compounding. So even within the 503B framework, not every substance is permissible.
Where This Meets Your Malpractice Policy
Medical professional liability policies are not standardized in the way many commercial policy forms are, and language varies considerably between carriers. That said, exclusions touching on unapproved products appear across the market in several recognizable forms:
- Exclusions for drugs, devices, or products not approved by the FDA, which can be read to reach compounded medications directly.
- Experimental or investigational treatment exclusions, which some carriers apply broadly.
- Off-label use exclusions or limitations, which are distinct from compounding but frequently overlap in the same clinical settings.
- Product liability and distribution exclusions, which matter if a practice dispenses, resells, or distributes compounded products rather than administering them directly to its own patients.
The exposure is not theoretical. Peer-reviewed analysis of the risks and liabilities of prescribing compounded medications notes that when a patient is harmed by a compounded medication, claims may be brought not only against the pharmacy and pharmacist who prepared it, but against the prescribing physician and the physician’s practice. Medical liability carriers themselves have published risk guidance on the subject, including Coverys on managing the risks of prescribing compounded drugs; MICA – Evaluating Risk When Prescribing Compounded Semaglutide; and PubMed Central – Safety of Compounded Medications.
The FDA has an entire section of its website devoted to Human Drug Compounding. Here are two links that are particularly helpful:
In other words, the claim can reach your practice, and the policy language determines whether it is a covered claim.
What Practices Should Do
- Read the exclusions section of your actual policy. Look specifically for FDA approval, experimental or investigational treatment, off-label use, and product or distribution language. If you cannot find it or cannot interpret it, ask your broker for a written coverage position.
- Disclose what you actually do. Carriers underwrite based on the services you report. A practice that has added compounded hormone therapy, peptides, or aesthetic injectables since its last application may be operating outside what the carrier believes it is insuring. Full disclosure at application and renewal is what makes coverage dependable.
- Ask about an endorsement. Where a practice has a legitimate clinical need for compounded medications, the answer is often a specific endorsement or an affirmative grant of coverage rather than a different policy. These exist, but they generally require proactive disclosure and are rarely automatic.
- Document your clinical rationale. Record why a compounded product was appropriate for the individual patient, whether an FDA-approved alternative existed, the informed consent discussion, and the sourcing facility. This documentation supports both the defense of a claim and the underwriting conversation.
- Vet your compounding source. Confirm 503A versus 503B status, review the facility’s inspection history, and keep records of your due diligence.
Review Your Healthcare Liability Program with Inszone
The gap between what a practice does clinically and what its policy covers tends to open quietly, one new service line at a time. Inszone’s healthcare liability specialists can review your medical professional liability policy against the services you actually provide, identify exclusions that reach compounded medications, and pursue the endorsements or markets that close the gap. Contact Inszone Insurance for a coverage review.
Frequently Asked Questions
Are compounded medications FDA approved?
No. Compounded drugs do not undergo FDA premarket review for safety, effectiveness, and quality, and they are exempt from FDA drug approval requirements. This is true of both 503A and 503B compounding.
Does using a 503B outsourcing facility mean the medication is FDA approved?
No. 503B registration means the facility is registered with FDA, subject to CGMP requirements, and subject to FDA inspection on a risk-based schedule. The compounded products themselves remain unapproved.
Is 503B still better than 503A for risk management?
Generally yes, because of the CGMP requirements and federal inspection framework. It reduces quality risk, but it does not resolve an FDA approval exclusion in a liability policy, because approval status is unchanged.
Does an FDA exclusion mean my claim will automatically be denied?
Not necessarily. Policy language varies significantly between carriers, and how an exclusion applies depends on the specific wording and the facts of the claim. That variability is exactly why the language should be reviewed before a claim arises rather than after.
Disclaimer: This article is provided for general informational purposes and does not constitute legal, medical, or coverage advice. Policy terms vary by carrier and by policy. Review your specific policy language and consult qualified counsel regarding your practice’s circumstances.